Original researchUse of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials

- Retrospective analysis to evaluate a 'basal-plus' regimen in type 2 diabetes.
- Glycated hemoglobin (HbA1c) and post-prandial glucose decreased at 6 months.
- Proportion of subjects with HbA1c < 7% increased.
- Prevalence of severe hypoglycemia was low and did not differ across groups.
- Neither age nor body mass index influenced the findings.

AimsTo evaluate the efficacy and safety of adding a single bolus dose of insulin glulisine to basal insulin ('basal-plus') in persons with type 2 diabetes.MethodsData from patients with poor glycemic control on oral antihyperglycemic drugs who were initiated on a 'basal-plus' regimen for up to 6 months were pooled from four randomized, multicenter studies. Glycated hemoglobin (HbA1c), fasting blood glucose, postprandial glucose (PPG), insulin dose and demographics were measured at baseline and end of study.Results711 patients with a mean age of 59.9 years and a mean duration of diabetes of 11.0 years were included in the analysis population. A 'basal-plus' regimen was associated with significant decreases in HbA1c and PPG at 6 months, an increase in glargine and glulisine doses and small, but statistically significant, changes in body weight and BMI in all patient subsets. The proportion of patients with HbA1c < 7% also increased in all populations studied, while the prevalence of severe hypoglycemia was low and did not significantly differ across patient groups.ConclusionsThese results suggest that the use of 'basal-plus' can achieve a good therapeutic response with a low risk of hypoglycemia and weight gain, regardless of a patient's age or BMI.